At the news
? BULLISHIMPACT 8/10 8-K filed Apr 16, 2026 at 06:05 ET
CareDx is divesting its lab products business to Eurobio Scientific for $170 million in cash to focus on core testing services, while reporting preliminary Q1 2026 revenue of $118 million with 48% year-over-year growth in testing services revenue. The transaction includes a 6-month transition services agreement and a distribution agreement for North America.
- Divesting lab products business to Eurobio Scientific for $170 million in cash
- Preliminary Q1 2026 revenue of $118 million, up 39% year-over-year
- Testing services revenue of $91 million, up 48% year-over-year
- Testing volume of 54,900, up 17% year-over-year
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access